Abstract
* The manufacturer of Zecuity, a transdermal formulation of sumatriptan, which is used to treat migraine headache, has temporarily suspended sales, marketing, and distribution while it works with the FDA to investigate the reports of burns and scarring associated with the patch.
* Clinicians should immediately stop prescribing Zecuity and provide patients with an alternative migraine medication.